Price is one of the biggest barriers to GLP-1 weight-loss success and it's about to vanish. The global GLP-1 market already ballooned from $45.3 billion in 2024 toward a projected $122.3 billion by 2030. Now Eli Lilly (LLY) and Amazon (AMZN) have teamed up to tear down that wall.
Amazon's Delivery Muscle Meets Lilly's Oral Breakthrough
Amazon Pharmacy has announced it would stock Lilly's new once-daily oral GLP-1 pill, Foundayo, for adults with obesity or overweight plus weight-related conditions. Patients with a valid prescription can order through Amazon Pharmacy, see real-time stock and transparent pricing, and receive the drug the same day in nearly 3,000 cities and towns. That network expands to nearly 4,500 locations by year-end, with next-day options for remote areas and in-office kiosks at select One Medical clinics. The setup eliminates the uncertainty patients face when starting treatment.
Amazon has delivered GLP-1s since 2021 and now layers in automatic manufacturer coupons at checkout. The result is faster, simpler access that pairs Lilly's oral innovation with Amazon's logistics scale.
Pricing Power That Supercharges Demand
Foundayo costs as low as $1 per day – or $25 per month – with insurance and $5 per day – or $149 per month – for cash payers, with Lilly's coupons applied automatically. That's a game-changer. Injectable GLP-1s often carry higher out-of-pocket costs and require refrigeration plus weekly shots. An oral pill at these prices puts the therapy within reach for millions more Americans who previously balked at the expense or hassle.
Lilly already offers additional patient discounts through its programs, further lowering the barrier. Let's break it down: Lilly's own data shows what happens when access improves. Mounjaro and Zepbound together generated $36.5 billion in 2025 revenue, up from roughly $16.5 billion the year before. Volume grew 46% in Q4 alone, even as realized prices dipped 5%. The new oral option, paired with same-day delivery, removes the last friction points and sets the stage for even steeper volume gains in 2026.
Lilly's Path to GLP-1 Dominance
Lilly now claims more than 60% of the U.S. market and 64% to 70% of new branded-obesity prescriptions. Full-year 2025 revenue hit $65.2 billion, up 45%, with 2026 forecast for $80 billion to $83 billion – roughly 23% growth at the midpoint.
Novo Nordisk (NVO), by contrast, guided for a 5% to 13% sales decline in 2026 after posting only 10% growth in 2025 that missed expectations. Its oral Wegovy pill faces stiff headwinds; analysts forecast just $2 billion in full-year sales, with injectable volumes recovering slowly amid pricing pressure and patent expirations in key markets. Foundayo's $1-a-day insured price and Amazon's instant delivery create a one-two punch that could accelerate the shift. In short, Lilly is about to own the market.
Bottom Line
Lilly remains a stock to own for its GLP-1 leadership. The Foundayo-Amazon deal rewrites the competitive map, potentially lifting Lilly's 2026 sales well above guidance while Novo struggles. Amazon gains a modest pharmacy tailwind – its segment remains tiny relative to its $700-plus billion total revenue, but the real winner for investors is LLY, as this partnership turns affordability into market dominance.
Comments
Log in or sign up to join the conversation.